New drug cocktail aims to beat back a tough leukemia
NCT ID NCT04385290
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether adding two targeted drugs, midostaurin and gemtuzumab ozogamicin, to standard chemotherapy can help people with newly diagnosed acute myeloid leukemia (AML) who have certain genetic changes. About 214 participants will receive the combination in two phases: first to find the safest dose, then to see if it improves remission and survival. The goal is to better control the disease and prevent relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- midostaurin and gemtuzumab ozogamicin (drugs added to standard chemotherapy)
- What this could lead to
- If it works, this combination could improve remission rates and delay relapse for people with certain genetic types of AML.
- What could go wrong
- This is an early-phase trial (phase 1/2), so safety and effectiveness are not yet proven. The added drugs may increase side effects like liver toxicity or infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gemeinschaftsklinikum Mittelrhein gGmbH
RECRUITINGKoblenz, 56068, Germany
-
Johann Wolfgang Goethe-Universität
RECRUITINGFrankfurt am Main, 60590, Germany
-
Klinikum Chemnitz gGmbH
RECRUITINGChemnitz, 09116, Germany
-
Klinikum Mannheim gGmbH
RECRUITINGMannheim, 68167, Germany
-
Klinikum Nürnberg-Nord
NOT_YET_RECRUITINGNuremberg, 90419, Germany
-
Krankenhaus Barmherzige Brüder
RECRUITINGRegensburg, 93049, Germany
-
LMU Klinikum, Campus Großhadern
RECRUITINGMünchen, Bavaria, 81377, Germany
-
Philipps-Universität Marburg Fachbereich Medizin
RECRUITINGMarburg, 35043, Germany
-
Rems-Murr-Klinikum Winnenden
RECRUITINGWinnenden, 71364, Germany
-
Robert-Bosch-Krankenhaus
RECRUITINGStuttgart, 70376, Germany
-
Rotkreuzklinikum München gGmbH
RECRUITINGMünchen, 80634, Germany
-
Universitätsklinikum Aachen
RECRUITINGAachen, 52074, Germany
-
Universitätsklinikum Augsburg
NOT_YET_RECRUITINGAugsburg, 86156, Germany
-
Universitätsklinikum Dresden
RECRUITINGDresden, 01307, Germany
-
Universitätsklinikum Essen
RECRUITINGEssen, North Rhine-Westphalia, 45147, Germany
-
Universitätsklinikum Halle
RECRUITINGHalle, 06120, Germany
-
Universitätsklinikum Heidelberg
RECRUITINGHeidelberg, 69120, Germany
-
Universitätsklinikum Jena
RECRUITINGJena, 07740, Germany
-
Universitätsklinikum Leipzig
RECRUITINGLeipzig, 04103, Germany
-
Universitätsklinikum Münster
RECRUITINGMünster, 48149, Germany
-
Universitätsklinikum Schleswig-Holstein
RECRUITINGKiel, 24105, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?